- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
教学课件课件PPT医学培训课件教育资源教材讲义
Primary Care Today
Educational Conference and Medical ExpositionToronto, Ontario / May 8-10, 2011;The Optimal Management of Diffuse Vascular Disease: Clinical Implications of the Landmark REACH Registry;Program Rationale;Learning Objectives;Framingham Heart Study:Atherothrombosis Reduces Life Expectancy;Framingham Heart Study:;Cardiovascular Event Ratesin 68,000 Outpatients with AtherothrombosisRegistry Results;REACH: Purpose;Must include
Signed
Written
Informed
Consent
Patients aged
≥45 years
;North America;;What Does REACH Add to Our Current Understanding of Atherothrombosis?;Baseline Data;;;Physician Profile;;Diffuse Vascular Disease;;;;1-Year Outcomes;;;1-year cardiovascular event rates as function of number of symptomatic disease locations*;Other outcomes leading to hospitalization since baseline;Major adverse event rates at one year as a function of age: total population;Geographical Variation of 1-year Cardiovascular Event Rates;Undertreatment of Risk Factors at Study Entry;Take-Home Messages;Atherothrombosis;Atherothrombosis has Multiple Manifestations;Atherothrombosis: A Generalized and Progressive Disease;What Types of Lesions Cause MI?;Pathology: Plaque Fissuring;0;Epidemiology of Atherothrombotic Manifestations in Canada;Peripheral Arterial Diseaseand theCanadian PAD Guidelines;Question 2;Often asymptomatic, under-diagnosed, under-recognized, and under-treated
16% of North America and Europe has PAD, corresponding to 27 million people
Of these, 16.5 million are asymptomatic
;CCS Guidelines: Diagnosis of PAD;Edinburgh Questionnaire;Measuring ABI;Question 3;
Local consequences in the leg include:
Intermittent claudication
Tissue loss including sepsis and major amputations
PAD is a marker of disease in other vascular beds
Fatal and non-fatal cerebral and coronary vascular events;Patients with Previous Atherothrombotic Events are at Increased Risk of Further Events;Consequences of PAD ;Risk of Death is Increased in Patients with Both Asymptom
您可能关注的文档
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】Evolution of Renal Replacement Therapy(57p).ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】Failure Modes and Effects Analysis (FMEA).ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】FLAT MAIL PREPARATIONOPTIMIZATION Issue #81.ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】Focus on Dialysis and Kidney Transplant.ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】Focus on Dialysis.ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】Glutamine therapy.ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】Hemodynamic Monitoring and Transthoracic Lines.ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】IMPLEMENTATION & USE of CRRT in PEDIATRIC INTOXICATIONS.ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】INSUFFICIENZA RENALE ACUTA.ppt
- (精编)【持续性肾脏替代治疗CRRT英文精品课件】Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units results from a multicenter prospective epidemiological survey.ppt
文档评论(0)